Celiac panel: why a negative result doesn't rule it out

What the celiac comprehensive panel actually tests

The celiac disease comprehensive panel is a blood test that screens for celiac-specific immune activity. It combines four key components: tTG-IgA (tissue transglutaminase IgA), the primary screening marker in most adults; EMA-IgA (endomysial antibody), highly specific for active disease; DGP IgA/IgG (deamidated gliadin peptides), useful in young children and when IgA is low; and total IgA, which confirms whether IgA-based results are valid or whether IgA deficiency is skewing them.

How gluten triggers the celiac antibody response

Picture the small intestine as a finely tiled mosaic built for absorbing nutrients. In celiac disease, gluten fragments slip through the gut lining and are modified by an enzyme called tissue transglutaminase, making them more visible to the immune system. In people who carry the genetic variants HLA-DQ2 or HLA-DQ8, immune cells present these modified fragments, activate T cells, and produce antibodies against both the gluten fragments and the enzyme itself. The collateral damage flattens the villi responsible for absorption — which is why iron levels drop, bones thin, and energy flags.

Gluten exposure is the primary driver of this process. The more consistent the exposure, the more sustained the immune response. Remove gluten and the antibody response winds down over months as inflammation cools and villi repair. EMA tracks closely with active disease; tTG-IgA is sensitive and useful for both diagnosis and follow-up; DGP antibodies are particularly helpful in younger children or when IgA is low. Broader inflammation or illness can occasionally blur the picture, but the key signal is trend over time rather than any single number.

The panel does not confirm active intestinal damage — biopsy remains the diagnostic standard in adults. Antibodies alone do not substitute for endoscopic confirmation.

Reading negative, equivocal, and positive panel results

Negative result

A negative panel — all antibodies below the lab's reference cutoff — can mean no celiac disease is present. However, it can also reflect insufficient gluten intake before testing, early or patchy disease, or selective IgA deficiency making IgA-based tests look deceptively normal. That is why total IgA is included in the panel and why IgG-based tests such as DGP-IgG or tTG-IgG step in when IgA is low. There is also a rare entity called seronegative celiac disease, in which antibodies are negative despite biopsy-proven villous damage. Genetic testing for HLA-DQ2 or DQ8 can be useful in difficult cases: a negative HLA result makes celiac disease very unlikely. A negative result is a data point to interpret alongside diet history, genetics, and, if needed, tissue biopsy — not a standalone reassurance.

Equivocal or borderline result

Unlike cholesterol, there is no "optimal" target here. These are threshold-based immunoassays, and a borderline result sits near the lab's cutoff without clearly falling on either side. Different labs use different assay kits and units, so a borderline result in one lab may read slightly differently in another — that is how immunoassays work, not a flaw. Context matters: children under two can show different antibody patterns than adults, and selective IgA deficiency makes IgA-based tests unreliable. The single most important caveat is that gluten must be consumed for at least several weeks before and during testing. If you have already gone gluten-free, antibodies often fall and results can appear falsely reassuring. A borderline result warrants clinical follow-up rather than a self-directed conclusion.

Positive result

A clearly elevated tTG-IgA while eating gluten strongly points toward celiac disease, especially when EMA is also positive. In pediatrics, a tTG-IgA approximately ten times the upper limit of normal combined with a positive EMA can be so specific that some European guidelines allow diagnosis without a biopsy in select cases. In adults, biopsy confirmation remains standard in many practices, per U.S. guidelines from the American College of Gastroenterology. Other conditions — certain autoimmune diseases and some chronic liver disorders — can nudge tTG upward, though EMA remains highly specific. Repeat elevations over time while on a gluten-containing diet carry more diagnostic weight than a single elevated result.

Why celiac panel results can mislead readers

Several factors can make celiac panel results unreliable independent of whether celiac disease is truly present or absent.

• Gluten intake before testing. Gluten exposure is not a confounder to minimize — it is the necessary pre-test condition. Going gluten-free before testing, even partially, suppresses antibody production and can produce false-negative results. For diagnostic testing, gluten consumption of at least one to two slices of bread equivalent per day for six to eight weeks before the draw is required.
• Selective IgA deficiency. IgA deficiency is more common in people with celiac disease than in the general population. When total IgA is low, tTG-IgA and EMA results are unreliable; IgG-based tests (DGP-IgG, tTG-IgG) become the appropriate readout instead.
• Biotin supplementation. High-dose biotin can interfere with certain immunoassay methods and skew antibody results. Inform your clinician about supplement use before testing.
• Immunosuppressant use. Medications that blunt immune activity can suppress antibody production, making results harder to interpret even in the presence of active disease.
• Pregnancy. Pregnancy alters immune tone and nutrient demands, which can affect antibody patterns and the interpretation of borderline results.
• Age-related antibody patterns. Young children, particularly toddlers, may show different antibody responses than adults; clinicians often rely more on DGP antibodies in this age group.
• Cross-lab and cross-assay variability. Comparing results across different laboratories or assay versions adds noise to trend interpretation. Using the same lab and the same assay version across serial tests gives the most reliable signal.

Non-celiac gluten sensitivity and wheat allergy are distinct conditions; this panel will not diagnose either.

What to test alongside the celiac panel

The celiac panel identifies immune activity against gluten, but several companion tests reveal the downstream effects of intestinal damage and help identify co-occurring conditions.

• Ferritin — iron deficiency from impaired small-intestine absorption is one of the earliest celiac complications; low ferritin alongside a positive celiac panel confirms active malabsorption.
• Vitamin D (25-OH) — the proximal small intestine that celiac disease damages is the primary site for vitamin D absorption; low 25-OH vitamin D alongside positive celiac antibodies points to active mucosal impairment.
• Albumin — low albumin alongside positive antibodies in adults suggests more severe or long-standing malabsorption affecting protein synthesis.
• TSH — autoimmune conditions cluster; thyroid autoimmunity (Hashimoto's) co-occurs with celiac disease at rates above the general population, making TSH and TPO testing standard follow-up at diagnosis.
• Alkaline phosphatase (ALP) — elevated ALP can reflect bone metabolic consequences of reduced calcium and vitamin D absorption; low ALP is seen in zinc deficiency from malabsorption — both patterns warrant investigation at diagnosis.

Retesting the celiac panel after going gluten-free

The primary reason to retest the celiac panel after diagnosis is to monitor dietary adherence and track intestinal recovery on a gluten-free diet. tTG-IgA responds slowly to dietary change — levels typically decline significantly within 6–12 months of strict gluten elimination and can normalize within one to two years, depending on baseline levels and age. This timeline is driven by villous healing, which is a biological process that takes months. Retesting at 8–12 weeks after starting a gluten-free diet is generally premature and usually reflects noise rather than meaningful mucosal change.

A reasonable retest cadence is every 6–12 months on a gluten-free diet until antibodies normalize, then annually thereafter. Persistently elevated antibodies after dietary change suggest ongoing gluten exposure — accidental or otherwise — rather than treatment failure. For this reason, using the same laboratory and the same assay version across serial tests is important; cross-lab comparison introduces variability that can obscure a real trend.

For anyone who has not yet started a gluten-free diet and is pursuing a first-time diagnosis, gluten must be consumed at the equivalent of at least one to two slices of bread per day for six to eight weeks before testing. Starting a gluten-free diet before completing the diagnostic workup — including biopsy if indicated — can make the diagnosis significantly harder to establish.

When celiac results warrant a GI referral

A positive tTG-IgA and EMA while eating gluten is a clear signal to involve a gastroenterologist. In adults, the next step is typically a duodenal biopsy to confirm villous damage — antibodies alone do not substitute for histological confirmation under current U.S. guidelines. In children with tTG-IgA approximately ten times the upper limit of normal and a positive EMA, some European guidelines permit diagnosis without biopsy in select cases; discuss the applicable standard with your clinician.

Certain patterns make prompt referral especially important. A positive panel combined with low ferritin, low vitamin D, or low albumin indicates active malabsorption with systemic consequences — untreated celiac disease drives iron deficiency anemia, low bone mineral density, and in children, growth delay. It also clusters with other autoimmune conditions including type 1 diabetes and autoimmune thyroid disease, so a positive result is often the starting point for a broader workup rather than the end of it.

If you are already gluten-free but never received a confirmed diagnosis, a gluten challenge under medical guidance — typically six to eight weeks of regular gluten consumption before repeat serology and biopsy — can resolve the question rather than leaving it open. Trending antibodies after gluten removal also provides a measurable way to confirm that the gut is healing: falling tTG-IgA alongside rising ferritin and vitamin D over months is evidence that the plan is working. The goal is not a perfect number but prevention of long-term complications and restoration of the absorptive function that supports lasting health.

Join Superpower today to access advanced biomarker testing with over 100 biomarkers.